I've been a cheerleader for this company and many people
I've been a cheerleader for this company and many people that I know own stock due to my enthusiasm in where the company is heading. I watched the price drop a a bit this week and honestly, I'm good with fluctuations in the share prices as long as the long term outlook has promise.
Conference calls trigger a downward trend of the price and really that is an indication that CYDY really needs to focus and finish something. The company takes on more and more clinical trials that are hugely expensive but yet we haven't gotten any approvals or EUAs. The power of positive thinking is powerful but cold hard cash is needed to keep things moving consistently.
Those announcements about new injections, trials, and indications put pressure on the financial side of the house which would be mitigated with some type of revenue stream from some type of approval to balance the expenditures. I temper my excitement now when a call is announced just from lessons learned in the past but have hopes that one day soon, there will be an announcement that will put things in high gear moving forward.
As I always say, I am here until there is unbelieveable success or failure of this company and I still believe it will be success. Not selling any of my shares but I wonder how can we do anything with any other indication when we haven't finished HIV? That approval was so close and yet here we are many months later and still no news on where that stands. I hear there are many different groups working on different indication approval but I'm still not sure the focus of the management team is meeting expections of the share holders.
I'll keep on believing and I really hope LL can fill part of the void that is so desperately needed right now. One good break can make all the difference in the world and it is coming.
Good Luck To Us All and please stay safe out there.
9
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Professor Plaxco’s Dynamic Role at Nutromics Some folks start their day with breakfast and coffee, but Nutromics is grabbing headlines by introducing Professor Kevin Plaxco as the new Chief Scientific Officer. This strategic shift, made public on September 7, 2026, signals Nutromics’ ambition to amplify its DNA-based sensing footprint. As they gear up to launch their...
Continue Reading
AI Transformation: Hard Reality or Strategic Opportunity? The future of work. That’s what everyone’s buzzing about lately, isn’t it? AI poised to shake every nook and cranny. You're either riding the wave or getting crushed by it. It’s no longer some distant prospect—the challenge is right here, now. Come September 23, Zellis Connect 2026 is plunging headfirst...
Continue Reading
Change Is Brewing in Europe's Telecom Markets Seems like Europe's telco scene is simmering. Over half of consumers in major European markets are giving their mobile providers the side-eye, ready to jump ship. That's putting the heat on operators who once banked on loyalty programs to keep their customer base intact. Diverse Loyalty Challenges Across Europe What's...
Continue Reading
Hyundai Drives Into Europe's Football Arena Football fever just turned electric with Hyundai allying itself with the UEFA Champions League. We're not talking about sidelines. We're smack dab in the center field of a multi-year partnership starting with the 2026/27 season. Folks, if you think this is just Hyundai shaking hands for brand exposure, think again. This is...
Continue Reading
EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...
Continue Reading
D-Wave Quantum Under Legal Microscope Alright, folks, let's dive headfirst into some dicey financial waters with D-Wave Quantum Inc. (NASDAQ: QBTS). This quantum computing company is finding itself in a bit of a pickle following some rough second-quarter results that left investors scratching their heads. If you bought into the hype and are feeling the sting in your...
Continue Reading
Under the shadows of Manhattan's skyline, something more than a regular service took shape. The New Yorker Hotel hosted an impassioned gathering of the Family Federation for World Peace and Unification. These folks weren't just saying their prayers; they were making a call—loud and resonant—for the release of Dr. Hak Ja Han. The Power of Collective Voices Gathering in...
Continue Reading
Revolution in Packaging: Southeast Asia Steps Up Get ready for a wake-up call in the world of packaging, folks; the Southeast Asian market is taking a sharp turn toward sustainability and technological advancement, as highlighted by WEPSEA 2026's recent wrap-up in Shanghai. Far from a mere exhibition, this gathering served as the crucible for change, where old-school...
Continue Reading
The New Gold Standard in Safety for Small EVs Hop into your favorite auto forum and you'll hear more than a buzz—it's a full-blown ruckus. The reason? GAC’s AION UT just nabbed a 2026 Euro NCAP Five-Star Safety Rating. Now, this isn’t just another accolade in a crowded trophy room; it’s a statement, a seismic shift in how small electric vehicles stack up in terms...
Continue Reading
Cuffless BP Monitoring: Changing the Game for AF and HF Ever thought a finger ring could revolutionize blood pressure monitoring? Well, welcome to the future—Sky Labs' ring-type CART monitor has just rocked the scene at the ESC Congress 2026 in Munich. This isn't sci-fi, folks; it's where health tech meets reality, and it's shaking the very foundations of how we manage...
Continue Reading
Top 5 Most Recently Viewed Articles
Lynkwell Amplifies Growth Plans for North American Expansion Lynkwell, a leading player in energy infrastructure, is set to embark on an exciting journey into 2025. With a focus on meeting the growing demands of the evolving electric vehicle (EV) market, Lynkwell is making significant investments to enhance its capabilities and expand its footprint across North America....
Continue Reading
Overview of Recent Trends in Private Student Loans In the recent semi-annual Private Student Loan Report released by Enterval Analytics, insights into the current status of private student loans reveal a stable repayment landscape. Since Enterval focuses on the private student loan market, their findings shed light on how borrowers are adapting their financial strategies...
Continue Reading
StemCyte's Major Achievement in Cord Blood Therapy StemCyte has made significant strides in regenerative medicine, specifically with its Hematopoietic Progenitor Cell (HPC) Cord Blood therapy. The company recently announced that it has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) aimed at treating...
Continue Reading
Novo Nordisk's Significant Job Cuts Novo Nordisk, a leading pharmaceutical company in diabetes care, has announced a major workforce reduction, cutting 9,000 jobs, which amounts to about 11.5% of its employees. This decision reflects the intense market pressure the company faces from its competitor, Eli Lilly. Restructuring for Financial Efficiency The restructuring...
Continue Reading
Elevating Research with One Helix One Helix emerges as a landmark project in life sciences, representing a new era of innovation and sustainable architecture. Located within a prominent university medical center, this facility is not just a building; it is a commitment to fostering scientific advancements. Completely leased to AstraZeneca, One Helix is designed to elevate...
Continue Reading